baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Dare Bioscience/ US23666P2002 /

2024-09-19 9:21:14 PM	Chg. -0.07	Volume	Bid-	Ask-	High	Low
3.27USD	-2.10%	100 Turnover: 327	-Bid Size: -	-Ask Size: -	3.27	3.27

GlobeNewswire 08-26 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings ...

GlobeNewswire 08-13 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from th...

GlobeNewswire 08-12 Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire 08-05 Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and...

GlobeNewswire 07-19 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

GlobeNewswire 06-27 Daré Bioscience Announces Reverse Stock Split

GlobeNewswire 06-24 Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results ...

GlobeNewswire 05-14 Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire 05-09 XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

GlobeNewswire 05-07 Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and ...

GlobeNewswire 05-02 Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

GlobeNewswire 04-30 Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 F...

GlobeNewswire 04-30 XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfoli...

GlobeNewswire 04-23 Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contrace...

GlobeNewswire 04-11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...

GlobeNewswire 03-28 Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

GlobeNewswire 03-21 Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webc...

GlobeNewswire 03-19 Repligen Appoints Maggie A. Pax to Board of Directors

GlobeNewswire 02-22 Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISS...

GlobeNewswire 01-31 Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cre...

GlobeNewswire 01-26 Daré Bioscience Announces Executive Team and Board of Directors Changes

GlobeNewswire 01-17 Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

GlobeNewswire 01-04 Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transfor...

GlobeNewswire 2023-12-26 Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

GlobeNewswire 2023-12-20 Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from th...

Dare Bioscience/ US23666P2002 /

If you wish to receive reply to your feedback, please provide your email address.